AI for Bio · Model

RFantibody

De novo antibody design pipeline for specified epitopes: generate backbones, design sequences, filter by structure

AntibodiesNonprofit instituteUnited StatesActive中文

Overview

NameRFantibody · aliases: RFantibody
Full nameNo separate expanded name
Ambiguous names (not auto-linked)None
FamilyNot a family entry. Single-model entry, not a family
OrganizationUniversity of Washington Institute for Protein Design
Organization typeNonprofit institute
CountryUnited States
Model classDe novo antibody design pipeline
DomainAntibodies
First release · preprint
Basis: bioRxiv v1 preprint (single-domain antibody version); the code repository creation date is not used source
Other milestones
  • Preprint v1: · bioRxiv v1 source
  • Journal online: · Nature online publication source
  • Code release: · GitHub adds JSON input and TCR-MHC support source
Latest update† partly verified · code release
Basis: GitHub code release adding JSON input and TCR-MHC support
Later items are a docs site (2026-09-23) and a licence clarification covering weights (2026-11-05); whether these count as updates is a policy call
Note: The later docs and licence edits are not folded into this field; marked unverified source
The most recent sourced event, not a claim that nothing changed since.
StatusActive · Code release within 12 months
OpennessCode: Open · MIT
Weights: Open · MIT
MIT licence covers code and weights; no training code provided
Benchmarks reported0 counted · none of the 44
Wet-lab validation3 recorded campaigns
Unverified fields† latest_update
As of2026-11-16

What it does

A fine-tuned diffusion model generates backbones for a specified epitope, a sequence-design tool supplies sequences, and a fine-tuned folding model filters; it covers VHH, scFv and full-length antibody formats.

Benchmarks reported

None of the 44 benchmarks. This model is on the zero-pairing list.

How it evaluates itself: Yeast display of VHH designs; Affinity maturation (OrthoRep); Cryo-EM validation; scFv and full-length IgG designs

Other evaluations (outside the 44)

  • Affinity maturation (Wet-lab validation) Self-reported: Developers report initial binders matured to single-digit nM while keeping epitope selectivity
  • scFv and full-length IgG designs (Wet-lab validation) Self-reported: Developers extend the pipeline to scFv and IgG formats with yeast-display confirmation

Developers report: Developers report the first atomically accurate de novo antibody design to a specified epitope, validated by cryo-EM

Independent evidence: A competitor's preprint uses it as a baseline, and an independent compilation shows a low structure-filter pass rate (computational, not wet lab)

Training data

Group in Figure 7: Public data + wet lab for validation only.

ClassValueDetail
a. Public databasesYesDiffusion and folding models fine-tuned on public PDB antibody complexes
b. Private or licensed dataNo
c. Own wet-lab data used for trainingNo
d. Wet lab used only for validationYesYeast display, SPR, cryo-EM and affinity maturation used for validation only

Wet-lab validation

Every rate carries its numerator and denominator. Claims that could not be verified are shown as unverified, without numbers; different paper versions are separate entries.

Yeast display of VHH designs (Nature paper)
Targets 4 · Designs tested 9000 · Hits — · Success success rates range from 0% to 2% across targets; 28 VHHs confirmed by SPR · Best affinity —

Denominator basis: Four epitopes with about 9,000 designs per target; the developers give a 0%–2% success range and 28 VHHs confirmed by SPR; per-target percentages sit in supplementary material and are not cited
The 9,000 figure and the 0%–2% range are verified in the published paper, lifting the earlier unverified flag; developer-run

Self-reported · No sourced date · verified · source
E. coli expression arm (Nature paper)
Targets 3 · Designs tested 95 · Hits — · Success — · Best affinity —

Denominator basis: Three further targets with 95 designs each, measured by single-concentration SPR
Recorded separately from the yeast-display arm; developer-run

Self-reported · No sourced date · verified · source
Cryo-EM validation (Nature paper)
Targets — · Designs tested — · Hits — · Success — · Best affinity —

Denominator basis: Structures solved for selected complexes: one VHH complex at 3.0 Å and two scFv structures at 3.6 Å and 6.1 Å
Cryo-EM, not negative stain; the institutional news page's looser wording must not replace the paper's resolutions

Self-reported · No sourced date · verified · source

Background

  • Organization: The developer is a nonprofit protein-design institute at the University of Washington
  • Funding: Funders include NIH, Microsoft, Open Philanthropy, the Gates Foundation and HHMI
  • Products and partnerships: Related technology is licensed to an AI-native biotech company; some authors are co-inventors on a patent
  • Related models: RFdiffusion2 / RFdiffusion3, RF3, IgGM / IgGM-FM, tFold, Origin-1

Reading notes

  1. Only the 0%–2% range may be used; per-target percentages in the supplement cannot be cited
  2. The two arms (9,000 and 95 designs per target) differ greatly in scale and must be read separately
  3. No results reported on any of the 44 benchmarks

Caveats

  1. Whether the docs site and licence edits count as updates is a policy call; marked unverified
  2. All experiments were developer-run, not independent replications

Sources

  1. PubMed/PMC record (journal)
  2. bioRxiv preprint (preprint)
  3. Crossref record 10.1038/s41586-025-09721-5 (journal)
  4. GitHub repository RosettaCommons/RFantibody (repository)
  5. Official page ipd.uw.edu (company blog)

Corrections

2 corrections
FieldWasNowBasisFound
wetlab_validationElectron microscopy validation, no resolution givenCryo-EM at 3.0 Å / 3.6 Å / 6.1 Åsource2026-11-16
wetlab_validationThe 9,000-per-target figure and 0%–2% range marked unverifiedVerified in the published paper and citable; the 95-per-target expression arm is addedsource2026-11-16

Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.